News

Filter

Current filters:

LupuzorDiabetes

1 to 9 of 95917 results

FDA backs added indication for GSK’s Promacta

FDA backs added indication for GSK’s Promacta

27-08-2014

The Food and Drug Administration has approved UK pharma giant GlaxoSmithKline’s supplemental New Drug…

GlaxoSmithKlineHematologyLigand PharmaceuticalsPharmaceuticalPromactaRare diseasesRegulationRevoladeUSA

Pfizer and Merck to explore potential of Xalkori/pembrolizumab combo

Pfizer and Merck to explore potential of Xalkori/pembrolizumab combo

26-08-2014

US pharma giants Pfizer and Merck & Co have inked an agreement to explore the therapeutic potential of…

Merck & CoOncologypembrolizumabPfizerPharmaceuticalResearchXalkori

Health Canada OKs Biogen Idec’s hemophilia A therapy Eloctate

Health Canada OKs Biogen Idec’s hemophilia A therapy Eloctate

26-08-2014

Canadian regulator Health Canada has approved US Biotech major Biogen Idec’s Eloctate (antihemophilic…

Biogen IdecBiotechnologyCanadaEloctateHematologyRegulationSwedish Orphan Biovitrum

Recipharm inks deal with Isofol Medical on Modufolin

Recipharm inks deal with Isofol Medical on Modufolin

26-08-2014

Swedish contract development and manufacturing group Recipharm and Isofol Medical AB, a Gothenburg-based…

FinancialIsofol MedicalModufolinOncologyPharmaceuticalProductionRecipharmResearch

Advaxis and Merck & Co collaborate on prostate cancer

Advaxis and Merck & Co collaborate on prostate cancer

26-08-2014

US cancer immunotherapies firm Advaxis has entered into a clinical trial collaboration agreement with…

AdvaxisADXS-PSABiotechnologyLicensingMerck & CoOncologypembrolizumabResearch

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

26-08-2014

Ireland-headquartered biotech firm Alkermes has submitted a New Drug Application to the US Food and Drug…

AbilifyAlkermesaripiprazole lauroxilBiotechnologyNeurologicalRegulationUSA

1 to 9 of 95917 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top